Revolution Medicines to Participate in Upcoming Investor Conferences
11/09/2022 - 04:05 PM
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference.
Details of these events are as follows:
H.C. Wainwright 3 rd Annual Precision Oncology Virtual Conference Conference Date: November 14, 20225 th Annual Evercore ISI HealthCONx Conference Webcasts of the H.C. Wainwright and Evercore ISI fireside chats can be accessed at: https://ir.revmed.com/events-and-presentations . Archived replays of the webcasts will be available on the investors section of the company’s website for at least 14 days following the events.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI ) and RMC-6291(KRASG12C ) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D ), currently in IND-enabling development, RMC-8839 (KRASG13C ), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
RVMD Rankings
#2552 Ranked by Stock Gains
RVMD Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Redwood City
About RVMD
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
